China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Non-Current Deferred Tax Liability came in at $759628.0 in Q1 2026, up 3.74% YoY from $732241.0 in Q1 2025, and up 1.58% on a QoQ basis from $747805.0 in Q4 2025.
China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $759628.0 in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 3.74% year-over-year to $759628.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $759628.0 (up 3.74% YoY) and the FY2025 annual result came in at $747805.0, up 2.27% from the prior year.
- Non-Current Deferred Tax Liability grew to $759628.0 in Q1 2026, from $747805.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $827978.0 in Q1 2022 to a low of $727417.0 in Q2 2023.
- A 5-year average of $749763.4 and a median of $740828.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability fell 8.65% — and 2026, when it gained 3.74%.
- Tracing CPHI's Non-Current Deferred Tax Liability over 5 years: stood at $754698.0 in 2022, then decreased by 1.67% to $742114.0 in 2023, then fell by 1.47% to $731202.0 in 2024, then grew by 2.27% to $747805.0 in 2025, then gained by 1.58% to $759628.0 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $759628.0 (Q1 2026), $747805.0 (Q4 2025), and $739733.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 759,628.00 |
| Mar 31, 2026 | 759,628.00 |
| Dec 31, 2025 | 747,805.00 |
| Dec 31, 2025 | 747,805.00 |
| Sep 30, 2025 | 739,733.00 |
| Sep 30, 2025 | 739,733.00 |
| Jun 30, 2025 | 734,246.00 |
| Jun 30, 2025 | 734,246.00 |
| Mar 31, 2025 | 732,241.00 |
| Mar 31, 2025 | 732,241.00 |
| Dec 31, 2024 | 731,202.00 |
| Dec 31, 2024 | 731,202.00 |
| Sep 30, 2024 | 750,089.00 |
| Sep 30, 2024 | 750,089.00 |
| Jun 30, 2024 | 737,522.00 |
| Jun 30, 2024 | 737,522.00 |
| Mar 31, 2024 | 740,828.00 |
| Mar 31, 2024 | 740,828.00 |
| Dec 31, 2023 | 742,114.00 |
| Dec 31, 2023 | 742,114.00 |